High Blood Sugar After Menopause and the Estrogen Connection Nobody Explains

Quick answer. Insulin resistance rises sharply around menopause because estrogen does far more than manage your cycle. It also helps keep your muscle and liver cells listening to insulin's signal to clear sugar from your blood. A major review of 2 large clinical trials found that restoring estrogen signaling cut new cases of type 2 diabetes by 19 to 35 percent in postmenopausal women. Below is that research, the human study behind the shilajit angle, and an honest look at where the evidence stops.

The short answer, and why "I did everything right" keeps happening

If your fasting number has been climbing even though your plate has not changed, you are not imagining it and you are not failing at discipline.

Something measurable shifts in how your body handles sugar around menopause, and it has very little to do with willpower. It has to do with a hormone that was quietly doing a job you never had to think about, for your entire adult life, until it stopped.

The mechanism, estrogen keeps your cells listening to insulin

Insulin's job is simple to describe. After you eat, it goes to your muscle and liver cells and tells them to open up and pull sugar out of your bloodstream.

Estrogen's role in that process is less well known, but it is well documented. Estrogen acts through a receptor called estrogen receptor alpha, and that receptor supports how well your cells respond to insulin's signal, how long your insulin-producing beta cells survive, and how your body manages energy overall.

While estrogen is at premenopausal levels, this support runs in the background and nobody notices it. When estrogen drops at menopause, the support goes with it. Muscle and liver cells become less responsive to the same amount of insulin, fat tends to shift toward the middle of the body, and blood sugar that used to clear efficiently starts running higher for longer after the same meal.

That is the piece that usually goes unexplained. The plate did not change. The signal telling your cells to respond to insulin did.

2 large trials, 1 clear signal

The clearest human evidence for this comes from a 2017 review in the journal Endocrine Reviews, which pulled together data from major hormone therapy trials in postmenopausal women.

In the HERS trial, which followed 2,763 postmenopausal women, restoring estrogen signaling through hormone therapy reduced new cases of type 2 diabetes by 35 percent over 4 years compared to placebo. In the Women's Health Initiative trial, estrogen plus progestin therapy produced a 19 to 21 percent reduction in new, treated diabetes over 5.6 years.

Those are not small effects, and they were not measuring weight loss or exercise habits. They isolated estrogen itself as a variable and watched blood sugar outcomes move with it, in both directions, when it was present versus when it was not.

This is why the framing matters. Your rising numbers are not exclusively a diet problem or an exercise problem. They are, at least in part, a signaling problem that started when estrogen declined.

What this does not mean

To be direct about the limits here. This research is not a case for hormone therapy as a diabetes treatment, and it is not a claim that hormone therapy is approved for that purpose. It is evidence of a mechanism, that estrogen signaling and insulin sensitivity move together, which is a different thing from a treatment recommendation.

It also does not mean every case of rising blood sugar after menopause is caused only by estrogen. Genetics, weight, sleep, stress, and family history of diabetes all still matter. What the mechanism explains is why the same effort that worked at 45 can stop being enough at 55, even when nothing else about your habits has changed.

Where shilajit fits, and what the human research actually measured

This is where we want to be precise, because it would be easy to overstate this.

Shilajit is not a hormone. It does not add estrogen to your body. What the compound is studied for is helping to support your body's own estrogen signaling and cellular function, and 2 specific pieces of human research are relevant here.

The first is a study published in Diabetes Care, the flagship journal of the American Diabetes Association, in 2003. In it, 61 people with diabetes took shilajit for 30 days while staying on their unchanged diabetes medication, as their own controls. The researchers were not measuring blood sugar in this study. They were measuring oxidative stress, the cellular damage that wears on the very beta cells that produce insulin. The marker of that damage, a molecule called MDA, dropped by more than half, from 15.56 to 6.52 units, and a key antioxidant enzyme called catalase rose significantly.

That result matters because the pancreas's insulin-producing cells are worn down by exactly this kind of oxidative stress over years of elevated blood sugar. A study showing that shilajit reduced that damage marker in diabetic patients is evidence of a protective mechanism working underneath the surface. It is not evidence that shilajit lowered anyone's blood sugar, and we are not going to claim that it did.

The second is a 12 week, placebo controlled trial in 40 people with type 2 diabetes, which found that shilajit lowered LDL cholesterol by 13 percent, total cholesterol by 21 percent, and triglycerides by 16 percent, while raising protective HDL cholesterol by 14 percent. It also reduced markers of inflammation and improved the health of blood vessel linings. That is a real, measured result in a diabetic population, and it speaks to cardiometabolic health broadly, which matters enormously for anyone managing blood sugar, but it is a lipid and inflammation study, not a glucose study.

Put plainly, the honest read of the human research is that shilajit has been shown, in people with diabetes, to reduce a marker of the cellular damage that wears out the pancreas over time, and separately to improve cholesterol and inflammation markers. It has not been shown, in a published human trial, to lower blood sugar or reverse diabetes, and we will not tell you otherwise.

The breast cancer question, answered directly

If you have spent years avoiding anything connected to estrogen because of a family history of breast cancer, this question is probably already on your mind, and it deserves a straight answer rather than a footnote.

In laboratory research, the fulvic acid found in shilajit was tested directly against MCF-7 cells, the most common estrogen receptor positive breast cancer cell line used in research, alongside a second aggressive line, MDA-MB-231. It reduced the growth of both and pushed the cancer cells toward programmed cell death, while leaving normal, healthy breast cells unaffected in the same experiment.

That is the opposite of feeding hormone sensitive cancer growth. It is not a cancer treatment claim, and it is laboratory research rather than a human cancer trial, but it is a real, documented finding worth knowing if this fear has kept you away from anything estrogen related.

Safety, and the purity question worth asking

Shilajit is a mineral resin, not a drug, and it is not designed to force a glucose number down the way a prescription is. Across human clinical studies conducted on shilajit to date, zero serious adverse events have been reported.

Purity is still a fair question to ask of anything sourced from mineral rock, since untracked sources can carry heavy metal contamination from their geology. Optimum shilajit comes from the Altai mountains, is purified, and every batch is third party lab tested and heavy metal free, with the results posted in the open. We are a small, family owned company out of Florida, and a real person answers when you reach out. It comes in a box of tablets, not a loose powder that loses its fulvic acid content before it reaches you.

If you take diabetes medication, mention any new supplement to your pharmacist so timing and any interaction can be checked properly.

What this actually means for you

If your numbers have been climbing despite real effort, the research says there is a documented, hormonal reason that has nothing to do with your discipline. Estrogen supported your insulin sensitivity for your entire adult life without you ever needing to think about it, and that support declined when estrogen did.

That explains the why. It is not a glucose-lowering supplement. What the human research on shilajit does show, honestly, is a documented reduction in the oxidative damage that wears down the cells that make your insulin, and improvements in the cholesterol and inflammation markers that travel alongside insulin resistance. Those are real, worthwhile findings on their own, sitting next to your existing plan rather than replacing it.

If you want a food-form resin backed by that human research, you can find Optimum Shilajit at https://www.liveoptimum.co/products/optimum-shilajit

Frequently asked questions

Does menopause really raise the risk of insulin resistance and type 2 diabetes?

Yes. A 2017 review in Endocrine Reviews found that restoring estrogen signaling through hormone therapy reduced new cases of type 2 diabetes by 35 percent in 1 large trial and by 19 to 21 percent in another, in postmenopausal women, isolating estrogen as a direct factor in blood sugar control.

Why does the same food spike my blood sugar more now than it did in my 40s?

Estrogen supports the signaling that keeps muscle and liver cells responsive to insulin. As it declines at menopause, that responsiveness weakens, so a meal that cleared efficiently at 45 can leave sugar circulating longer at 55, even with no change in diet.

Does shilajit lower blood sugar or reverse diabetes?

No. The human research available comes from a Diabetes Care study measuring oxidative stress, and a separate lipid and inflammation trial in diabetics, neither of which measured a glucose-lowering effect. We do not claim shilajit lowers blood sugar or treats diabetes.

Is it safe to take shilajit if I am worried about estrogen and breast cancer?

Shilajit is not a hormone and adds no estrogen to your body. Laboratory research found the fulvic acid in shilajit reduced the growth of estrogen receptor positive breast cancer cells while sparing normal breast cells. Zero serious adverse events have been reported across human shilajit studies to date.

References

1. Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. Endocrine Reviews. 2017;38(3):173-188. https://pubmed.ncbi.nlm.nih.gov/28323934/
2. Saxena N, Dwivedi UN, Singh RK, Kumar A, Saxena C, Saxena RC, Saxena M. Modulation of Oxidative and Antioxidative Status in Diabetes by Asphaltum Panjabinum. Diabetes Care. 2003;26(8):2469-2470. https://pubmed.ncbi.nlm.nih.gov/12882881/
3. Niranjan A, et al. Shilajit cardiometabolic randomized controlled trial in type 2 diabetics. International Journal of Ayurveda and Pharma Research. 2016. https://ijapr.in/index.php/ijapr/article/view/322
4. Rahmanibarouji M, et al. In vitro effects of shilajit on breast cancer cell lines MCF-7 and MDA-MB-231. 2020. https://pubmed.ncbi.nlm.nih.gov/34466597/
5. Stohs SJ. Safety and Efficacy of Shilajit (Mumie, Moomiyo). Phytotherapy Research. 2014;28(4):475-479. https://pubmed.ncbi.nlm.nih.gov/23733436/